Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb), which
kills about 2 million people annually. Furthermore, 2 billion people worldwide are latently …

Current tuberculosis (TB) treatment requires 6 months of combination therapy with isoniazid
(INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol for active TB and 9 months of INH …

The antituberculosis (anti-TB) drug rifampin (RIF) binds to the beta subunit of the RNA
polymerase (RpoB) of Mycobacterium tuberculosis , but the bactericidal responses triggered after …

Mycobacterium tuberculosis is exposed to hypoxia and acidity within granulomatous lesions.
In this study, an acidic culture model of M. tuberculosis was used to test drug activity …

The physiology of dormant Mycobacterium tuberculosis was studied in detail by examining
the gene expression of 51 genes using quantitative Reverse-Transcription Polymerase Chain …

The susceptibility of 211 clinical isolates of Mycobacterium tuberculosis complex (201 M.
tuberculosis and 10 Mycobacterium bovis isolates) to pyrazinamide (PZA) was assessed by the …

The activities of rifampin, rifapentine, bedaquiline, PA-824, clofazimine, nitazoxanide, isoniazid,
amikacin, moxifloxacin, niclosamide, thioridazine, and pyrazinamide were tested against …

The development of antibiotic-resistant bacteria is a worldwide health-related emergency that
calls for new tools to study the bacterial metabolism and to obtain fast diagnoses. Indeed, …

Objective/background Heterogeneous mixtures of cellular and caseous granulomas coexist
in the lungs of tuberculosis (TB) patients, with Mycobacterium tuberculosis (Mtb) existing …

Tuberculosis (TB) is a major infectious disease worldwide. Over recent years, TB caused by
multidrug-resistant (MDR) Mycobacterium tuberculosis strains (resistant to at least isoniazid …